Akebia Therapeutics And U.S. Renal Care Sign Supply Contract Enabling USRC Attending Physicians To Prescribe Vafseo For Patients On Dialysis As Deemed Clinically Appropriate
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics has signed a supply contract with U.S. Renal Care, allowing USRC physicians to prescribe Vafseo for dialysis patients. This partnership could enhance Akebia's market reach and product adoption.
October 07, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akebia Therapeutics has entered into a supply contract with U.S. Renal Care, enabling the prescription of Vafseo for dialysis patients. This partnership may increase the adoption and sales of Vafseo, potentially boosting Akebia's revenue.
The supply contract with U.S. Renal Care allows Akebia to expand its market reach for Vafseo, potentially increasing sales and revenue. This strategic partnership is likely to have a positive impact on Akebia's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90